Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Acurx Pharmaceuticals Stock (NASDAQ: ACXP) stock price, news, charts, stock research, profile.
Open1.600 | Close1.530 |
Vol / Avg.68.348K / 33.436K | Mkt Cap19.898M |
Day Range1.460 - 1.600 | 52 Wk Range1.530 - 4.610 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.290 | -0.280 | 0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-13 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 13.00 |
2023-08-15 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Lowers | 14.00 | 13.00 |
2023-05-15 | HC Wainwright & Co. | Ed Arce | Reiterates | BuyBuy | Maintains | - | 14.00 |
2023-04-11 | HC Wainwright & Co. | Ed Arce | Reiterates | Buy | Maintains | - | 14.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
ACXP | Acurx Pharmaceuticals | -4.38% | 19.9M |
VINC | Vincerx Pharma | 1.21% | 19.7M |
ALZN | Alzamend Neuro | -3.93% | 21.3M |
VIRI | Virios Therapeutics | 0% | 18.1M |
CLRB | Cellectar Biosciences | 14.61% | 24.4M |
You can purchase shares of Acurx Pharmaceuticals (NASDAQ: ACXP) through any online brokerage.
Other companies in Acurx Pharmaceuticals’s space includes: Vincerx Pharma (NASDAQ:VINC), Alzamend Neuro (NASDAQ:ALZN), Virios Therapeutics (NASDAQ:VIRI), Cellectar Biosciences (NASDAQ:CLRB) and Evaxion Biotech (NASDAQ:EVAX).
The latest price target for Acurx Pharmaceuticals (NASDAQ: ACXP) was reported by HC Wainwright & Co. on Wednesday, September 13, 2023. The analyst firm set a price target for 13.00 expecting ACXP to rise to within 12 months (a possible 749.67% upside). 7 analyst firms have reported ratings in the last year.
The stock price for Acurx Pharmaceuticals (NASDAQ: ACXP) is $1.53 last updated September 22, 2023 at 8:00 PM UTC.
There is no dividend information for Acurx Pharmaceuticals.
Acurx Pharmaceuticals’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Acurx Pharmaceuticals.
Acurx Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.